Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Köhnke, Thomas ^a,b   Krupka, Christina ^a,b   Tischer, Johanna ^a   Knösel, Thomas ^c   Subklewe, Marion ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

ALL; Blinatumomab; Combination therapy; Immune checkpoints; Immunotherapy; T cells

Indexed keywords

BLINATUMOMAB; CD19 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; BISPECIFIC ANTIBODY; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BLAST CELL; BONE MARROW EXAMINATION; CASE REPORT; CELL COUNT; CONTINUOUS INFUSION; FEVER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTE COUNT; MALE; PRE B LYMPHOCYTE; PROTEIN EXPRESSION; T LYMPHOCYTE; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; METABOLISM; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ADULT; ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD274; ANTIGENS, CD3; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84943302629     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0213-6     Document Type: Article

References (22)

1. Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7(1):58.
2. Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8(1):104.
3. Zugmaier G, Klinger M, Schmidt M, Subklewe M. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies. Mol Immunol. 2015;67(2 Pt A):58-66.
4. Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, singlearm, phase 2 study. Lancet Oncol. 2014;16(1):57-66.
5. Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. 2013;5 Suppl 1:5-11.
6. Bassan R. Toward victory in adult ALL: blinatumomab joins in. Blood. 2012;120(26):5094-5.
7. Eyre TA, Collins GP. Immune checkpoint inhibition in lymphoid disease. Br J Haematol. 2015;170(3):291-304.
8. Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6(1):74.
9. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24-33.
10. Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112(9):1421-7.
11. Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 2013;162(3):313-25.
12. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65.
13. Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meet Abstr. 2014;32(15-suppl):3005. May 20.
14. Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7(1):70.
15. Krupka C, Kufer P, Kischel R, Zugmaier G, Bogeholz J, Köhnke T, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123(3):356-65.
16. Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J. Immunotherapy in cancer: a combat between tumors and the immune system; you win some, you lose some. Front Immunol. 2015;26:6.
17. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med Am Assoc Adv Sci. 2012;4(127):127ra37-7.
18. Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3-BiTE® antibody construct AMG 330: reversing a T-cell induced immune escape mechanism. Leukemia: Nature Publishing Group; 2015.
19. Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Immunotherapy of non-Hodgkin's lymphomas. Hematol Am Soc. 2001;2001(1):221-40.
20. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol. 2012;22(1):3-13.
21. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Publ Group. 2012;12(4):278-87.
22. Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs Landes Bioscience; 2009;1(3):222-9.